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A 35-year-old female hepatitis B virus carrier chimpanzee was infused with one dose of a mixture
of human monoclonal antibodies 9H9 and 4-7B (antibodies against hepatitis B virus surface
antigen; HBsAg). Blood samples were taken before and up to 3 weeks after infusion. HBsAg and
antibodies against HBsAg (anti-HBs) were quantified by radioimmunoassay and enzyme immuno-
assay. Free anti-HBs was never detected. Thirty min after the start of the infusion the HBsAg level
was minimal with maximum loading of the chimpanzee HBsAg with human immunoglobulin. HBsAg
complexes could be dissociated by acid treatment. The HBsAg level was completely restored on day
7. Similar results were obtained for the preS1-containing particles that may represent the
infectious viral particles in the chimpanzee serum. A mouse monoclonal anti-HBs (HBs.OT40) was
found to compete with 9H9 in artificial immune complexes with the pre-treatment HBsAg from the
chimpanzee. Used as a conjugate, HBs.OT40 yielded a maximum decrease in the signal in the
30 min sample compared to non-competing anti-HBs conjugates. This indicates binding of HBsAg
with 9H9 in the circulation of the chimpanzee. Immune-complexed 4-7B could not be detected by
its corresponding 4-7B peptide conjugate, probably due to its low concentration in the complexes.
It is concluded that human monoclonal anti-HBs can effectively reduce the level of HBsAg in serum
from this chronic carrier. Monoclonals 9H9 and 4-7B may complement each other due to their
different mechanisms of inactivation, probably with higher efficiency than that monitored by our
HBsAg screening assays.
Introduction
Hepatitis B virus immunoglobulin (HBIg) has been used for
more than a decade to prevent hepatitis B virus (HBV) infection
in newborns of hepatitis B virus surface antigen (HBsAg)-
positive mothers and in adults after needle stick accidents.
More recently HBIg has been introduced as a prophylactic
against recurrent hepatitis B in liver transplant recipients
(Samuel et al., 1993). Restricted availability of HBIg, partially
due to the discovery of new blood-borne viruses such as
human T-lymphotropic virus types 1 and 2, human immuno-
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deficiency virus types 1 and 2, and hepatitis C virus has
stimulated the introduction and application of (human) mono-
clonal antibodies (Ehrlich et al., 1992).
Recently, HBsAg escape mutants were observed in
vaccinated children (HBIg and HBV vaccine) (Oon et al., 1996)
and in liver transplant recipients treated with monoclonal as
well as polyclonal anti-HBs (Carman et al., 1996). An alternative
treatment of liver transplant recipients with nucleotide
analogues, which looked very promising at first, is hampered at
present by the emergence of virus resistance caused by
changes in the polymerase gene (Bartholomew et al., 1997).
It has been suggested that a combination of carefully
selected monoclonal antibodies could prevent the appearance
of escape mutants. Recently, we studied the inhibitory activity
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of a mixture of two monoclonal antibodies in vitro (Heijtink et
al., 1995). One of these antibodies, 9H9, is directed against a
conformational epitope located in the ‘a ’ region, the other,
4-7B, is directed against a linear epitope at the C-terminal end
of the S protein (W. P. Paulij and others, unpublished data). In
HBV-positive serum from liver transplant recipients the 9H9
monoclonal antibody was effective against wild-type HBV
whereas the 4-7B monoclonal antibodies could also ‘neutralize ’
mutant HBV, including the Arg-145 variant (Busstra et al.,
1995).
Prior to administration of 9H9 and 4-7B antibodies to
chronically infected hepatitis B patients we studied the effect of
these monoclonal antibodies on the serum level of HBsAg (S
protein) and HBV (represented as preS1 protein) in a chronic
hepatitis B virus carrier chimpanzee.
Methods
+ Anti-HBs treatment of the chimpanzee. A 35-year-old female
chimpanzee weighing 52 kg was HBsAg-positive, anti-HBs-negative,
HBeAg-negative, anti-HBe-positive and HBV DNA-negative by solution
hybridization. HBsAg was of the mixed ad}ay type with major reading
of HBsAg}adw
#
. Several treatments, such as administration of anti-HBs,
interferon or a preS2-enriched HBsAg vaccine, were given to break the
carrier state, unfortunately without success. The last treatment ended 5
years before the start of the present study.
The animal was housed at the Laboratory for Experimental Medicine
and Surgery in Primates (LEMSIP) of the New York Medical Center,
New York, USA. The study was approved by the LEMSIP Institutional
Animal Care and Use Committee.
In January 1995 this chimpanzee was intravenously inoculated while
under anaesthesia (ketamine hydrochloride, 10–15 mg}kg) with a 1 :1
mixture on the basis of weight of human monoclonal anti-HBs 9H9
(3–64‹10& IU) and 4-7B (2–20‹10$ IU) (Biotest Pharma) in 50 ml PBS
with 1% human albumin. Pre-treatment samples were taken at both 2
months and 12 min prior to the start of therapy. Other samples were
taken at 10, 20 and 30 min, 1 h, 6 h, 12 h and 1, 2, 4, 7, 14 and 21 days
after the start of the infusion. The infusion was completed in 33 min.
Serum samples were stored at fi20 °C until use.
+ HBsAg and anti-HBs assays. HBsAg and anti-HBs levels were
evaluated by commercial radioimmunoassays (RIAs) (Ausria II, Ausab
IMx, Abbott Laboratories) and in experimental enzyme immunoassays
(EIAs) according to standard procedures. Experimental EIAs were
introduced for detection of preS1-containing particles and for detection
of 9H9 and 4-7B antibodies specifically.
Assay protocols. In EIA plates solid phase antibodies (anti-S, anti-preS1)
were used for capturing either HBsAg (S protein) or HBV (preS1 pro-
tein) from serum. The presence of captured S protein or preS1 protein
was analysed or quantified by anti-S or anti-preS2 (in case of preS1-
containing particles) conjugates. Human immunoglobulin (Ig) or mouse
Ig present in immune complexes with S protein or preS1 protein was
detected by anti-human Ig and anti-mouse Ig conjugates. These im-
mune complexes were captured by solid phase anti-S or anti-preS1.
For quantification of artificial immune complexes we used the
‘ inhibition in solution assay ’. In this assay antigen and antibody were pre-
incubated for 2 h at room temperature and the residual detectable amount
of antigen (S protein or preS1 protein) was measured using the standard
antigen detection assay (Heijtink et al., 1995).
To detect the preference for similar epitopes by two monoclonal
antibodies from different species of origin, captured HBsAg (on solid
phase anti-S) was subsequently loaded with the two antibodies. Binding
preferences were visualized using species-specific anti-Ig conjugates.
Test components. In the EIAs solid phase antibodies were mouse mono-
clonal HBs.OT40 (anti-S) (Organon Teknika), a combination of three
mouse monoclonals (anti-S), HBs.OT20, HBs.OT13 and HBs.OT16
(abbreviated as HBs.OT3M) (Organon Teknika), or sheep anti-preS1
(Organon Teknika). Mouse monoclonals HBs.OT40 (anti-S), HBs.OT42
(anti-S) (Organon Teknika) or OTB-anti-preS2 (Organon Teknika) were
used as conjugate (biotin}avidin–HRP labelling, Amersham). HRP-
labelled goat anti-human Ig (Sigma), sheep anti-human Ig (Amersham)
and rabbit anti-mouse Ig (Dako) were used for detection of human Ig
and mouse Ig in complexes. After peptide mapping the corresponding
4-7B peptide (Organon Teknika) was used as solid phase ‘ antigen ’ or
as conjugate (HRP).
HBsAg and preS1-Ag were assayed in sequential serum samples from
the chimpanzee. However, to ensure optimum assay systems and
reference material in in vitro experiments, we used HBsAg from the
hepatoma cell line HepG2 2.2.15 (ayw
$
), human HBsAg (Mat.O[adw
#
] ;
see Heijtink et al., 1995) and HBsAg}ayw
#
(P2 ; Reference HBsAg, Paris,
1977) as well.
Polyclonal anti-HBs (Hepatect) was obtained from Biotest. Stock
solutions of 9H9 and 4-7B contained 14550 IU}ml and 88 IU}ml,
respectively. Since the dilution curves for 9H9 and 4-7B were different we
expressed the concentration of 9H9 and 4-7B preferentially as a dilution
factor for stock rather than in IU}l.
+ Immune complex dissociation. Immune complexes were de-
graded by the acid dissociating method of Nishanian et al. (1990). In
short, 50 ll 0–5 M HCl was added to a 100 ll sample and incubated for
15 min at 37 °C. Subsequently, 50 ll 0–5 M NaOH was added and
incubation was continued for another 5 min at room temperature. To
stabilize the pH after NaOH treatment samples were diluted in 1 M
Tris–HCl (pH 7–6) which did not influence the pH reduction achieved
with 0–5 M HCl (to pH 1–9).
Results
HBsAg and anti-HBs in chimpanzee serum during
treatment and follow-up
HBsAg was quantified in consecutive serum samples by
means of Ausria II (Abbott Laboratories) and by an ex-
perimental EIA (Fig. 1). HBsAg was standardized with the Paul
Ehrlich Institute standard for HBsAg. According to these two
assays the pre-treatment sample contained 36 lg}ml (RIA) or
49 lg}ml (EIA) HBsAg.
Anti-HBs (Ausab IMx, Abbott Laboratories) could not be
detected before (fi12 min), during (10, 20 or 30 min) or after
(1 h) infusion of monoclonal 9H9}4-7B. However, our ex-
perimental HBsAg EIA with solid phase mouse monoclonal
HBs.OT40 (anti-S) could detect an increase in human Ig on the
surface of the chimpanzee HBsAg in the first 24 h after infusion
of monoclonal anti-HBs.
HBsAg binding in radioimmunoassay inhibited by 9H9
and 4-7B
Previously we had established the 50% inhibitory concen-
trations (IC
&!
) of 9H9 (110 IU}l) and 4-7B (12 IU}l) for HBsAg
(Mat.O, 6 ng}ml) in human serum in an ‘ inhibition in solution
BFDA
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Fig. 1. Quantification of HBsAg from a chronically infected chimpanzee
after infusion with a 1:1 (w/w) mixture of human monoclonal 9H9 and
4-7B by radioimmunoassay (hatched bars) (Ausria II, Abbott Laboratories)
and an experimental HBsAg EIA (solid bars) using solid phase mouse
monoclonal HBs.OT40 and conjugated mouse monoclonal HBs.OT42
(Organon Teknika). Infusion lasted 33 min. Immune-complexed human Ig
was monitored simultaneously with the HBsAg EIA (unfilled bars) using
goat anti-human Ig as conjugate and presented as absorbance at 450 nm.
assay ’ (Heijtink et al., 1995). In this assay, HBsAg is pre-
incubated with anti-HBs and the residual detectable amount of
HBsAg is measured by means of a commercial HBsAg assay
(Ausria II, Abbott Laboratories). The 50% reduction rate is
estimated from a titration curve. In a similar experiment with
the chimpanzee HBsAg (pre-treatment sample) the same result
was obtained for 9H9 (IC
&!
110 IU}l 9H9 with 6 ng}ml
chimpanzee HBsAg). Somewhat lower amounts of 4-7B
(4 IU}l) were needed for chimpanzee HBsAg compared to
human HBsAg (12 IU}l). In this experiment a maximum
inhibition rate of 94% and 100% was obtained for 9H9 and
4-7B, respectively.
Binding of human HBsAg in EIA inhibited by 9H9 and
4-7B
In order to assess 9H9 and 4-7B in immune complexes we
changed from the radioimmunoassay to an (experimental)
enzyme immunoassay. In our experimental HBsAg EIA we
started with mouse monoclonal HBs.OT40 (anti-S) as solid
phase and mouse monoclonal HBs.OT42 (anti-S) as the
conjugate. Both antibodies recognize conformational epitopes.
Unexpectedly, in experiments with our reference HBsAg
(Mat.O) not only did the IC
&!
of 9H9 and 4-7B determined by
EIA and RIA differ but the IC
&!
of 9H9 also decreased 500-fold
relative to the IC
&!
of 4-7B. Replacing the solid phase
HBs.OT40 (anti-S) in our EIA by a combination of three
different anti-S-specific mouse monoclonals (HBs.OT20}
HBs.OT13}HBs.OT16; abbreviated to HBs.OT3M) reduced
the relative difference in IC
&!
between 9H9 (1}20480) and
4-7B (1}2048) for HBsAg–Mat.O binding by a factor of 10
(see Fig. 5a). Since the change in relative difference in IC
&!
was
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Fig. 2. Solid phase anti-preS1 was subsequently loaded with HBsAg/ayw2
(P2), anti-S (9H9 and HBs.OT40) and conjugated anti-mouse Ig or anti-
human Ig. HBsAg was applied to solid phase anti-preS1 in a fixed
concentration (dilution 1/100); the second and third incubation steps
were performed with titrated amounts of HBs.OT40 and a fixed amount
(1/105) of 9H9 (curves a, d), respectively, and similarly with a titrated
amount of 9H9 and a fixed amount of HBs.OT40 (curves b, c). Monitoring
was by anti-mouse Ig (curves a, c) and anti-human Ig (curves b, d).
Results are given in absorbance at 450 nm.
attributed predominantly to 9H9, these experiments suggest
that HBs.OT40 and 9H9 may compete for the same epitope
region on HBsAg. Due to the lower sensitivity of our
experimental EIAs compared to the commercial RIA, larger
amounts of HBsAg (RIA, 6 ng}ml ; EIA, 70 ng}ml) and
antibodies had to be used.
Mouse HBs.OT40 (anti-S) and human 9H9 react with
similar epitopes on human and chimpanzee HBsAg
To confirm the affinity of mouse HBs.OT40 (anti-S) and
human 9H9 for the same epitope region on HBsAg, experi-
ments were performed with HBsAg}ayw
#
(P2, HBsAg panel of
reference sera, Paris, 1977) on solid phase anti-preS1. Anti-
preS1 was introduced to avoid competition between the anti-
HBs antibodies in the samples and the anti-HBs in the solid
phase. P2 was chosen because of its favourable preS1}S ratio
and low level of background human Ig reactivity.
Solid phase sheep anti-preS1 was loaded with a fixed
amount of HBsAg}ayw
#
, which resulted in an absorbance
of 0–600 with HBs.OT.42 (anti-S) as conjugate. After the
incubation with HBsAg}ayw
#
this HBsAg was subsequently
loaded with (human) 9H9 and mouse HBs.OT40 (anti-S), or
vice versa, in separate incubation steps. Finally, the presence of
human 9H9 or mouse HBs.OT40 (anti-S) was analysed with
anti-human Ig or anti-mouse Ig conjugates, respectively. Fig.
BFDB
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Table 1. Human monoclonal 9H9 and mouse monoclonal
anti-S (HBs.OT40) may use similar epitopes on
chimpanzee HBsAg fixed to solid phase anti-preS1
In successive incubation steps chimpanzee HBsAg was bound to solid
phase anti-preS1 and a titrated amount of 9H9 (low, 1}10’ ; high,
1}10%) or diluent was added. A third incubation was performed with
diluent or a fixed amount of HBs.OT40 (low, 1}10’ ; high, 1}10%).
Finally, conjugates were applied as indicated. Chimpanzee pre-
treatment serum, dilution 1}16 : A
%&!
0–083 with conjugated anti-
mouse Ig ; A
%&!
0–975 with conjugated HBs.OT42. Anti-HBs, low and
high dilutions from stock solution. Results in absorbance at 450 nm.
2nd Incubation
9H9 Concn 4th Incubation
Diluent Low High 3rd Incubation Conjugate
1–319 1–550 1–824 Diluent Anti-human Ig
0–931 0–718 0–137 Low HBs.OT40 conc Anti-mouse Ig
1–770 1–693 1–060 High HBs.OT40 conc Anti-mouse Ig
2 (curve a) illustrates the reduction in absorbance with dilution
of HBs.OT40 in the first anti-HBs incubation step. The amount
of HBs.OT40 was measured with anti-mouse Ig conjugate after
rinsing the wells and applying a fixed amount of 9H9 to each
of the wells. Fig. 2 (curve d) shows that the absorbance of 9H9
as measured with anti-human Ig increases in parallel with the
reduction of the amount of mouse HBs.OT40 (anti-S).
Comparable results were obtained with incubation of
HBs.OT40 (fixed amount) and 9H9 (titrated amount) in the
reverse order (curves b, c).
Experiments were repeated on a small scale with the
chimpanzee pre-treatment HBsAg. The summary in Table 1
shows that increasing the amount of 9H9 on the chimpanzee
pre-treatment HBsAg on solid phase sheep anti-preS1 reduced
the possibility of binding mouse HBs.OT40 (anti-S) antibodies.
The reverse experiment, loading the chimpanzee HBsAg with
a titrated amount of mouse HBs.OT40 (anti-S) and subse-
quently loading with a fixed amount of 9H9, confirmed these
results. These experiments suggest that human 9H9 and mouse
HBs.OT40 (anti-S) bind to the same epitope region of the
chimpanzee HBsAg.
PreS1-Ag titration by HBs.OT42 (anti-S) and
HBs.OT40 (anti-S) conjugates in the chimpanzee
serum samples
Chimpanzee serum samples were assayed by means of the
sheep anti-preS1 solid phase EIA using the two mouse anti-S
conjugates HBs.OT40 (anti-S) and HBs.OT42 (anti-S) in
parallel. Mouse OTB-anti-preS2 conjugate was included as a
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Fig. 3. The residual amount of preS1-Ag-containing particles in serum
samples from a chimpanzee obtained during and after administration of a
mixture of human monoclonal antibodies was titrated with conjugated anti-
S (HBs.OT40, + ; HBs.OT42, *), anti-preS2 (OTB-anti-preS2, ^) and
anti-human Ig (_), simultaneously. The bars represent the ratios of the
absorbance signals of conjugated HBs.OT40 and HBs.OT42.
control. Fig. 3 shows that HBsAg measured with the
conjugated HBs.OT40 (anti-S) decreased from the start of the
infusion, in contrast to the similar signals obtained at fi12, 10
and 20 min with conjugated HBs.OT42 (anti-S) or anti-preS2.
The lowest ratio of HBs.OT40 to HBs.OT42 was found with
the 30 min sample. This time-point coincides with the highest
human Ig signal. These results suggest that the binding of
HBs.OT40 conjugate to the chimpanzee HBsAg is restricted
due to the presence of immune-complexed 9H9 in the same
epitope area.
Dissociation by acid treatment of the chimpanzee
HBsAg from complexes with human monoclonal anti-
HBs
To confirm the presence of HBsAg–human monoclonal
anti-HBs immune complexes the chimpanzee serum samples
were treated according to the acid immune complex dis-
sociation method of Nishanian et al. (1990).
As a pilot experiment artificial immune complexes of
HepG2 2.2.15 HBsAg and 9H9 were prepared. HepG2 2.2.15
HBsAg is devoid of specific}non-specific reactive human Ig in
contrast to the chimpanzee pre-treatment HBsAg. Indeed,
close to the IC
&!
concentration of 9H9 for HepG2 2.2.15
HBsAg, a two- to threefold increase in HBsAg signal was
observed after acid treatment compared to non-treated
samples. These results were obtained with solid phase mouse
monoclonal HBs.OT40 (anti-S) with a restricted binding
capacity for HBsAg–9H9 complexes due to shielding of the
HBs.OT40 epitope by 9H9. Mouse monoclonal HBs.OT42
(anti-S) was used as conjugate. The presence of human Ig on
BFDC
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Fig. 4. Chimpanzee serum samples before and after infusion of human
monoclonals 9H9 and 4-7B were subsequently incubated with 0–5 M HCl
and 0–5 M NaOH to liberate HBsAg from immune complexes. Samples
were assayed in EIA with a mixture of mouse anti-HBs monoclonals
(HBs.OT20, HBs.OT13 and HBs.OT16; abbreviated as HBs.OT3M) as
solid phase and mouse monoclonal HBs.OT42 (anti-S) as conjugate.
Absorbance before treatment (cross-hatched bars) ; after treatment
(unfilled bars) ; and ratio of the signals after/before treatment (solid bars).
HepG2 2.2.15 after pre-incubation with 9H9 was confirmed
with anti-human Ig conjugate.
To avoid competition between human 9H9 and solid phase
mouse monoclonal HBs.OT40 (anti-S) in chimpanzee samples
with suspected HBsAg–9H9–4-7B complexes the solid phase
HBs.OT40 (anti-S) was replaced by a combination of three
other mouse monoclonal antibodies with anti-S specificity
(HBs.OT3M). Fig. 4 shows that after HCl treatment the ratio of
treated}untreated HBsAg for chimpanzee samples varied with
a maximum deviation at 30 min after the start of the infusion.
This is in accordance with results for human Ig on HBsAg
particles, as detected by solid phase anti-S and anti-preS1
(Fig. 3).
Detection of 4-7B in immune complexes with
chimpanzee HBsAg
By standard pepscan procedures the linear epitope (4-7B
peptide) corresponding to the 4-7B antibody was found at the
C-terminal end of the S protein (W. P. Paulij and others,
unpublished data). When used as a solid phase peptide or as a
conjugate it could react with conjugated 4-7B antibody and
solid phase 4-7B antibody, respectively, in our EIA protocol.
Unfortunately, solid phase peptide 4-7B could not bind the
suspected HBsAg–4-7B complex (chimpanzee, 30 min sample).
In the reverse experiment, solid phase HBs.OT3M (anti-S)
could bind 9H9}4-7B complexed HBsAg (30 min sample) but
4-7B could not be detected with the peptide conjugate.
Chimpanzee HBsAg (168 h sample) was loaded on the
HBs.OT3M (anti-S) plate and subsequently incubated with
4-7B antibodies. Both HBsAg and 4-7B were used in titrated
amounts (twofold dilutions 1}25–1}100 and 1}2–1}32,
respectively). These artificial HBsAg–4-7B complexes bound
to solid phase anti-S and could be detected with our 4-7B
peptide conjugate. Thus, it seems that in the samples obtained
shortly after 9H9}4-7B administration chimpanzee HBsAg–
4-7B complexes were not present in sufficient amounts to be
detected by the 4-7B peptide conjugate.
Finally, the consecutive chimpanzee samples were assayed
using solid phase HBs.OT3M (anti-S) and conjugated
HBs.OT42 (anti-S) in comparison to the combination of
solid phase 4-7B and conjugated 4-7B. Although it was
expected that in the latter assay binding of the HBsAg–4-7B
complex to solid phase 4-7B and 4-7B conjugate would be
inhibited the most, the signal ratio for the two protocols
revealed the highest reduction was only 7% for the 30 min
sample.
Binding of preS1-Ag in EIA inhibited by 9H9 and 4-7B
As an alternative for the still cumbersome experiments to
detect neutralization of HBV in tissue cultures, we assayed the
inhibitory effect of 9H9 and 4-7B in an in vitro assay using solid
phase anti-preS1. This system may resemble the adherence of
HBV to human hepatocytes by means of preS1 epitopes.
Experiments with chimpanzee preS1–HBsAg did not yield
complete inhibition at very high levels of 9H9 or even 4-7B.
This may be explained by the relatively large amounts of S
epitopes compared to preS1 epitopes in a sample without HBV
DNA-positive particles. Therefore, we changed to the HBV
particle-rich reference serum (Mat.O). The specificity of preS1-
Ag binding was confirmed by the complete loss of signal from
HBsAg in the anti-preS1 assay but not in the HBsAg assay
(solid phase HBs.OT3M), after treatment of preS1–HBsAg
with trypsin (results not shown) (Itoh & Fujisawa, 1986 ; Petit
et al., 1987). In both assays mouse monoclonal anti-S
(HBs.OT42) was used as conjugate.
Both 4-7B and polyclonal human anti-HBs (Hepatect ;
results not shown) were able to reduce the binding of HBsAg
particles to solid phase anti-S (Fig. 5a) and solid phase anti-
preS1 (Fig. 5b) by more than 97%. Similarly, 9H9 could inhibit
the binding of HBsAg particles to solid phase anti-S by about
70% and to solid phase anti-preS1 by about 60%. The IC
&!
increased three- to fivefold from the preS1 assay to the S assay.
This may be explained by the higher input of HBsAg needed
for the preS1 assay and the binding of antibodies to HBsAg
particles without preS1-Ag. Experiments were repeated with
HepG2 2.2.15 HBsAg to exclude an influence of native human
BFDD
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Fig. 5. Inhibitory activity of human monoclonals 9H9 (^) and 4-7B (*)
in ‘ inhibition in solution ’ assays with solid phase anti-S (HBs.OT3M) (a)
and anti-preS1 (b). HBsAg/S/preS1 from the reference sample (Mat.O)
was pre-incubated with titrated amounts of 9H9 or 4-7B. The residual
amount of HBsAg was monitored with conjugated anti-S (HBs.OT42).
Human Ig on the surface of these residual particles bound to solid phase
anti-S/preS1 was monitored with an anti-human Ig conjugate (_, 9H9;
+, 4-7B). Results in absorbance at 450 nm. (a) 50% inhibitory dilution
4-7B, 1/2048; 9H9, 1/20480. (b) 50% inhibitory dilution 4-7B, 1/768;
9H9, 1/3840 (50% from maximum of inhibition in this experiment).
Ig normally present on HBsAg particles. The incomplete
inhibition by 9H9 in the preS1 assay was confirmed.
Furthermore, monitoring of human Ig (HBsAg-complexed
9H9 or 4-7B) in the same experiments (Fig. 5) indicated that
4-7B prevents the adherence of HBsAg particles to solid phase
anti-S as well as anti-preS1 (return to baseline signal at full
inhibition). In contrast, a relatively stable amount of 9H9
remained associated with the HBsAg particles at saturation
levels of 9H9.
This phenomenon was investigated more directly by using
4-7B and 9H9 as solid phase anti-HBs in EIAs. Post-treatment
chimpanzee HBsAg (168 h) was incubated with 9H9 or 4-7B
and residual HBsAg assayed on the 4-7B and 9H9 solid phases,
respectively. As a reference 9H9 could inhibit chimpanzee
HBsAg by as much as 60% on solid phase HBs.OT3M (anti-S).
However, 9H9 could inhibit chimpanzee HBsAg by only 25%
(dilutions 1}20000 to 1}10) on the 4-7B solid phase. In the
reverse experiment, 4-7B could inhibit HBsAg binding to solid
phase 9H9 from 20% at a dilution of 1}40000 to 92% at a
dilution of 1}4, with a gradual increase over this concentration
range. HBsAg detection was always by HBs.OT42 (anti-HBs)
conjugate.
These results strongly suggest that 9H9 and 4-7B may
have different mechanisms for inhibition or ‘neutralization ’ of
HBV particles.
In a separate experiment we investigated the effect of
inhibiting the activity of the 1 :1 (w}w) mixture of 9H9 and
4-7B on HBsAg (Mat.O) with solid phase mouse monoclonal
HBs.OT3M (anti-S) and conjugated mouse monoclonal
HBs.OT42 (anti-S). The additive rather than synergistic effect
of mixing, as described earlier (Heijtink et al., 1995), was
confirmed. Spiking the 9H9 samples with an equal amount of
4-7B resulted in a relatively small change (16%) in the IC
&!
to
a higher dilution. However, the inhibition curve showed the
4-7B characteristics and inhibition now reached 99%. The
accompanying human Ig curve resembled the 4-7B}human Ig
curve. These results suggest that at the level of maximal
efficacy of 9H9, spiking 9H9 with 4-7B changes the additive
effect of 4-7B to a complementary effect, thereby also changing
the type of ‘neutralization ’.
‘Neutralization’ of chimpanzee HBsAg by human
monoclonal 9H9/4-7B in vitro and in vivo
In an earlier experiment we found the IC
&!
of 9H9 and 4-7B
for human HBsAg to be 110 IU}l and 12 IU}l, respectively. In
this in vitro assay inhibitory activity occurred for HBsAg at a
concentration of 6 ng}ml after incubation of equal volumes.
According to our RIA results with chimpanzee HBsAg 50%
inhibition was obtained at 110 IU}l and 4 IU}l with 6 ng}ml
HBsAg and equal volumes. It may be estimated that the
minimum amount of HBsAg in the circulation of the chim-
panzee is about 90 mg (36 lg}ml HBsAg in serum, 2–5 l
serum).
For 50% inhibition of 90 mg HBsAg about 1650000 IU
9H9 or 300000 IU 4-7B will be needed in vitro. The
chimpanzee received about 364000 IU of 9H9 and 2200 IU of
4-7B which is about 20% of the amount needed for only 50%
inhibition in vitro with 9H9 and less than 1% needed for 50%
inhibition by 4-7B. This may explain the relatively low
concentrations and the absence of detectable 4-7B in HBsAg
immune complexes. Furthermore, the reduction by 80% of
detectable HBsAg in serum between 30 min and 24 h after the
start of the infusion may point to elimination of immune-
complexed virus particles rather than shielding of epitopes.
Discussion
About 30 min after the start of the infusion of monoclonal
anti-HBs, the amount of detectable HBsAg in chimpanzee
blood had reached its lowest level. The pre-treatment level of
HBsAg was restored after about 7 days.
This study confirms, although in part by indirect evidence,
that human monoclonal anti-HBs administered intravenously
BFDE
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to an HBsAg carrier chimpanzee can form immune complexes
in vivo. The immune complexes could be destroyed by acid
treatment.
Based on rough calculations and using in vitro inhibition
experiments for estimates of in vivo results, it is assumed that
the amounts of 9H9 and 4-7B administered to the chimpanzee
could be responsible for only a small reduction in accessible
HBsAg in the circulation. It seems likely that, in addition to
covering the 9H9 and 4-7B epitopes on HBsAg, immune
complexes containing HBsAg may be eliminated from the
circulation by phagocytosis of the immune aggregates by
macrophages.
The aim of this study was to learn the fate of 9H9 and 4-7B
human monoclonal antibodies in the circulation of a chronically
infected chimpanzee in the first hours and days after adminis-
tration. For the linear epitope of the human monoclonal 4-7B
it was relatively easy to select a corresponding peptide for
specific detection of 4-7B in immune complexes. However,
probably due to the low concentration of 4-7B, we were not
able to detect HBsAg-complexed 4-7B in chimpanzee serum
with conjugated 4-7B peptide nor were we able to bind the
presumed HBsAg–4-7B immune complexes to solid phase
4-7B peptide. Artificial complexes with high loads of 4-7B were
positive with the 4-7B peptide conjugate in the same assay.
By chance, one of our mouse anti-HBs monoclonal
antibodies (HBs.OT40) was found to compete with 9H9 for
the same epitope region of HBsAg. Using HBs.OT40
specificity and assuming that in vitro and in vitro processes are
alike, we tested the accessibility of the 9H9 epitope region on
chimpanzee HBsAg during 9H9}4-7B treatment. The results
suggest that up to 30 min after the start of the infusion there
is reduced HBsAg activity with HBs.OT40 (anti-S) conjugate
compared to HBs.OT42 (anti-S) conjugate due to loading of
HBsAg in the circulation by 9H9. At 30 min after the start of
the infusion the level of HBsAg was minimal, as assayed by
solid phase anti-HBs or anti-preS1 and conjugated anti-S or
anti-preS2. The anti-human Ig signal confirmed maximum
complexing of HBsAg with 9H9}4-7B in the 30 min sample.
Furthermore, the experiment with solid phase anti-preS1 and
conjugated anti-preS2 strongly suggested that HBsAg particles
were removed from the circulation and not just covered with
9H9}4-7B in view of similar findings for solid phase anti-S and
anti-preS1.
Earlier experiments on ‘ inhibition in solution ’ of HBsAg by
9H9 had already revealed that this human monoclonal
antibody could not completely inhibit the binding of HBsAg to
solid phase anti-HBs in contrast to human monoclonal 4-7B.
The use of solid phase anti-preS1 with anti-preS2 detection
confirmed the deviant behaviour of 9H9 once more. Even
extremely large amounts of 9H9 did not change the rate of
inhibition of binding to solid phase anti-S markedly (Fig. 5a).
The lowest rate of inhibition (20%) by titrated amounts of 9H9
was observed for chimpanzee HBsAg measured on solid phase
4-7B. In the reverse experiment, inhibition by 4-7B and
detection on solid phase 9H9, more than 90% inhibition
was found. Could it be that 4-7B is more effective in the
aggregation of particles and 9H9 in complete shielding?
Our observations stress the need for models based on
infectivity assays, whether in tissue cultures or in animals.
From this chimpanzee study we have learned that monoclonal
anti-HBs, and probably polyclonal anti-HBs as well, may help
to eliminate virus particles from the circulation without
completely blocking or shielding the main epitopes used for
detection of HBsAg in diagnostic assays.
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